331 related articles for article (PubMed ID: 28334439)
41. KIT amplification and gene mutations in acral/mucosal melanoma in Korea.
Yun J; Lee J; Jang J; Lee EJ; Jang KT; Kim JH; Kim KM
APMIS; 2011 Jun; 119(6):330-5. PubMed ID: 21569090
[TBL] [Abstract][Full Text] [Related]
42. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
Ascierto PA; Dummer R; Gogas HJ; Flaherty KT; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; de Groot JWB; Loquai C; Gollerkeri A; Pickard MD; Robert C
Eur J Cancer; 2020 Feb; 126():33-44. PubMed ID: 31901705
[TBL] [Abstract][Full Text] [Related]
43. Analysis of KIT expression and gene mutation in human acral melanoma: with a comparison between primary tumors and corresponding metastases/recurrences.
Dai B; Cai X; Kong YY; Yang F; Shen XX; Wang LW; Kong JC
Hum Pathol; 2013 Aug; 44(8):1472-8. PubMed ID: 23528861
[TBL] [Abstract][Full Text] [Related]
44. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
Ascierto PA; McArthur GA; Dréno B; Atkinson V; Liszkay G; Di Giacomo AM; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Yan Y; Wongchenko M; Chang I; Hsu JJ; Koralek DO; Rooney I; Ribas A; Larkin J
Lancet Oncol; 2016 Sep; 17(9):1248-60. PubMed ID: 27480103
[TBL] [Abstract][Full Text] [Related]
45. Tumour heterogeneity of mucosal melanomas during treatment with imatinib.
Schoenewolf NL; Urosevic-Maiwald M; Dummer R
Br J Dermatol; 2011 Aug; 165(2):419-24. PubMed ID: 21495997
[TBL] [Abstract][Full Text] [Related]
46. Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06).
Lee SJ; Kim TM; Kim YJ; Jang KT; Lee HJ; Lee SN; Ahn MS; Hwang IG; Lee S; Lee MH; Lee J
Oncologist; 2015 Nov; 20(11):1312-9. PubMed ID: 26424760
[TBL] [Abstract][Full Text] [Related]
47. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
[TBL] [Abstract][Full Text] [Related]
48. Upcoming strategies for the treatment of metastatic melanoma.
Spagnolo F; Queirolo P
Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
[TBL] [Abstract][Full Text] [Related]
49. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.
Guo J; Si L; Kong Y; Flaherty KT; Xu X; Zhu Y; Corless CL; Li L; Li H; Sheng X; Cui C; Chi Z; Li S; Han M; Mao L; Lin X; Du N; Zhang X; Li J; Wang B; Qin S
J Clin Oncol; 2011 Jul; 29(21):2904-9. PubMed ID: 21690468
[TBL] [Abstract][Full Text] [Related]
50. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics.
Woodman SE; Davies MA
Biochem Pharmacol; 2010 Sep; 80(5):568-74. PubMed ID: 20457136
[TBL] [Abstract][Full Text] [Related]
51. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.
Tang B; Yan X; Sheng X; Si L; Cui C; Kong Y; Mao L; Lian B; Bai X; Wang X; Li S; Zhou L; Yu J; Dai J; Wang K; Hu J; Dong L; Song H; Wu H; Feng H; Yao S; Chi Z; Guo J
J Hematol Oncol; 2019 Jan; 12(1):7. PubMed ID: 30642373
[TBL] [Abstract][Full Text] [Related]
52. Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma.
Nomura M; Oze I; Masuishi T; Yokota T; Satake H; Iwasawa S; Kato K; Andoh M
Int J Clin Oncol; 2020 May; 25(5):972-977. PubMed ID: 31938955
[TBL] [Abstract][Full Text] [Related]
53. Imatinib mesylate in combination with pembrolizumab in patients with advanced KIT-mutant melanoma following progression on standard therapy: A phase I/II trial and study protocol.
Hirai I; Tanese K; Fukuda K; Fusumae T; Nakamura Y; Sato Y; Amagai M; Funakoshi T
Medicine (Baltimore); 2021 Dec; 100(49):e27832. PubMed ID: 34889232
[TBL] [Abstract][Full Text] [Related]
54. A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial.
Li T; Christensen SD; Frankel PH; Margolin KA; Agarwala SS; Luu T; Mack PC; Lara PN; Gandara DR
Invest New Drugs; 2012 Apr; 30(2):741-8. PubMed ID: 20967484
[TBL] [Abstract][Full Text] [Related]
55. Somatic activation of KIT in distinct subtypes of melanoma.
Curtin JA; Busam K; Pinkel D; Bastian BC
J Clin Oncol; 2006 Sep; 24(26):4340-6. PubMed ID: 16908931
[TBL] [Abstract][Full Text] [Related]
56. Adjuvant vemurafenib in resected, BRAF
Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D;
Lancet Oncol; 2018 Apr; 19(4):510-520. PubMed ID: 29477665
[TBL] [Abstract][Full Text] [Related]
57. Distribution and clinical role of KIT gene mutations in melanoma according to subtype: a study of 492 Spanish patients.
Millán-Esteban D; García-Casado Z; Manrique-Silva E; Virós A; Kumar R; Furney S; López-Guerrero JA; Requena C; Bañuls J; Traves V; Nagore E
Eur J Dermatol; 2021 Dec; 31(6):830-838. PubMed ID: 33648909
[TBL] [Abstract][Full Text] [Related]
58. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
[TBL] [Abstract][Full Text] [Related]
59. Malignant Melanoma of Vulva and Vagina: A Histomorphological Review and Mutation Analysis--A Single-Center Study.
Rouzbahman M; Kamel-Reid S; Al Habeeb A; Butler M; Dodge J; Laframboise S; Murphy J; Rasty G; Ghazarian D
J Low Genit Tract Dis; 2015 Oct; 19(4):350-3. PubMed ID: 26225944
[TBL] [Abstract][Full Text] [Related]
60. The clinical significance of KIT mutations in melanoma: a meta-analysis.
Gong HZ; Zheng HY; Li J
Melanoma Res; 2018 Aug; 28(4):259-270. PubMed ID: 29746316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]